<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01381328</url>
  </required_header>
  <id_info>
    <org_study_id>Gepheral</org_study_id>
    <secondary_id>Merck Sharp &amp; Dohme Corp.</secondary_id>
    <nct_id>NCT01381328</nct_id>
  </id_info>
  <brief_title>GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance</brief_title>
  <official_title>GePheRal: Clinical Validation of the Genotypic Diagnosis of Hiv-1 Resistance to Raltegravir by Parallel Analysis of the Genotype and Phenotype Profiles of Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Vita-Salute San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Università Vita-Salute San Raffaele</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to correlate the different patterns of resistance mutations
      observed in vivo in patients failing RAL treatment with the fold-change resistance determined
      by the phenotypic assay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives are, as follows:

        -  to establish standardised genotypic assay for the HIV-1 pol gene region (region of
           interest, sensitivity, mutations involved as primary or compensatory changes, role of
           polymorphism present at baseline).

        -  to reach consensus on the algorithm interpretation of in house ex-vivo genotypic
           evaluations.

        -  to assess the genetic changes in RAL-failing patients under continuous drug pressure or
           drug discontinuation (dynamics of the reversion of resistance mutations).

        -  to evaluate in RAL resistant HIV-1 variants the changes in replication capacity (RC)
           (baseline vs. following-timepoints).

        -  to evaluate the immunological and virological trend associated with a
           raltegravir-regimen failure.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>- mean value of fold-change resistance determined by the phenotypic assay at baseline</measure>
    <time_frame>baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of fold-change resistance determined by the phenotypic assay with respect to baseline.</measure>
    <time_frame>24 and 48 hours, W1, W2, W3 and W4 upon discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genetic changes under continuous drug pressure or drug discontinuation with respect to baseline(dynamics of the reversion of resistance mutations)</measure>
    <time_frame>24 and 48 hours, W1, W2, W3 and W4 upon discontinuation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of the replication capacity with respect to baseline</measure>
    <time_frame>24 and 48 hours, W1, W2, W3 and W4 upon discontinuation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of HIV-RNA with respect to baseline</measure>
    <time_frame>24 and 48 hours, W1, W2, W3 and W4 upon discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in CD4, CD4%, CD8, CD8% with respect to baseline</measure>
    <time_frame>24 and 48 hours, W1, W2, W3 and W4 upon discontinuation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1 Infected Patients</condition>
  <condition>Fold-change Resistance</condition>
  <condition>Resistance Mutations</condition>
  <arm_group>
    <arm_group_label>RAL Group</arm_group_label>
    <description>HIV-1 infected patients failing to a RALTEGRAVIR-containing regimen</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (at least 18 years of age) treatment-experienced, HIV-infected subjects of
             either sex and of any race, failing to a RAL-containing regimen will be enrolled in
             the study

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Clementi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Vita-Salute San Raffaele Laboratory of Microbiology and Virology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonella Castagna, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Infectious Diseases, IRCCS San Raffaele Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonella Castagna, MD</last_name>
    <phone>0039022643</phone>
    <phone_ext>7934</phone_ext>
    <email>castagna.antonella@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabetta Carini, Msc</last_name>
    <phone>0039022643</phone>
    <phone_ext>7934</phone_ext>
    <email>carini.elisabetta@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Infectious Diseases, IRCCS San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Castagna, MD</last_name>
      <phone>0039022643</phone>
      <phone_ext>7934</phone_ext>
      <email>castagna.antonella@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Elisabetta Carini, MSc</last_name>
      <phone>0039022643</phone>
      <phone_ext>7934</phone_ext>
      <email>carini.elisabetta@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonella Castagna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Clementi, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell. 1991 Dec 20;67(6):1211-21.</citation>
    <PMID>1760846</PMID>
  </reference>
  <reference>
    <citation>Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005 Mar;4(3):236-48. Review.</citation>
    <PMID>15729361</PMID>
  </reference>
  <reference>
    <citation>Anker M, Corales RB. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs. 2008 Jan;17(1):97-103. Review.</citation>
    <PMID>18095922</PMID>
  </reference>
  <reference>
    <citation>Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007 Apr 14;369(9569):1261-9.</citation>
    <PMID>17434401</PMID>
  </reference>
  <reference>
    <citation>Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008 Jul 24;359(4):355-65. doi: 10.1056/NEJMoa0708978.</citation>
    <PMID>18650513</PMID>
  </reference>
  <reference>
    <citation>Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N. Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. AIDS. 2009 Feb 20;23(4):455-60. doi: 10.1097/QAD.0b013e328323da60.</citation>
    <PMID>19165083</PMID>
  </reference>
  <reference>
    <citation>Nakahara K, Wakasa-Morimoto C, Kobayashi M, Miki S, Noshi T, Seki T, Kanamori-Koyama M, Kawauchi S, Suyama A, Fujishita T, Yoshinaga T, Garvey EP, Johns BA, Foster SA, Underwood MR, Sato A, Fujiwara T. Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics. Antiviral Res. 2009 Feb;81(2):141-6. doi: 10.1016/j.antiviral.2008.10.007. Epub 2008 Nov 21.</citation>
    <PMID>19027039</PMID>
  </reference>
  <reference>
    <citation>Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, Kodama M, Endoh T, Oosugi E, Matsushita Y, Murai H, Fujishita T, Yoshinaga T, Garvey E, Foster S, Underwood M, Johns B, Sato A, Fujiwara T. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 2008 Nov;80(2):213-22. doi: 10.1016/j.antiviral.2008.06.012. Epub 2008 Jul 14.</citation>
    <PMID>18625269</PMID>
  </reference>
  <reference>
    <citation>Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009 Jan-Mar;11(1):17-29. Review.</citation>
    <PMID>19290031</PMID>
  </reference>
  <reference>
    <citation>Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, Katlama C, Calvez V, Marcelin AG. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008 Apr;52(4):1351-8. doi: 10.1128/AAC.01228-07. Epub 2008 Jan 28.</citation>
    <PMID>18227187</PMID>
  </reference>
  <reference>
    <citation>Menzo S, Monachetti A, Balotta C, Corvasce S, Rusconi S, Paolucci S, Baldanti F, Bagnarelli P, Clementi M. Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors. AIDS. 2003 Mar 28;17(5):663-71.</citation>
    <PMID>12646788</PMID>
  </reference>
  <reference>
    <citation>Sichtig N, Sierra S, Kaiser R, Däumer M, Reuter S, Schülter E, Altmann A, Fätkenheuer G, Dittmer U, Pfister H, Esser S. Evolution of raltegravir resistance during therapy. J Antimicrob Chemother. 2009 Jul;64(1):25-32. doi: 10.1093/jac/dkp153. Epub 2009 May 14.</citation>
    <PMID>19447792</PMID>
  </reference>
  <reference>
    <citation>Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother. 2009 Apr;63(4):795-804. doi: 10.1093/jac/dkp014. Epub 2009 Feb 16.</citation>
    <PMID>19221102</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>February 8, 2013</last_update_submitted>
  <last_update_submitted_qc>February 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Vita-Salute San Raffaele</investigator_affiliation>
    <investigator_full_name>Elisabetta Carini</investigator_full_name>
    <investigator_title>Professor Massimo Clementi</investigator_title>
  </responsible_party>
  <keyword>HIV-1 infected patients</keyword>
  <keyword>RALTEGRAVIR regimen</keyword>
  <keyword>genotypic evaluations</keyword>
  <keyword>phenotypic evaluations</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

